Bioxyne enters German medical cannabis market with $5.6M deal

Bioxyne Limited has officially entered the German medical cannabis sector through its subsidiary, Breathe Life Sciences (BLS), by securing a commercial supply agreement valued at a minimum of €3.2 million (approximately AUD 5.6 million) for the fiscal year 2026. This agreement, established with Farmakem d.o.o. and Adrex Pharmaceuticals GmbH, obligates the buyers to acquire and distribute at least 1,600 kilograms of medical cannabis flower produced by BLS, adhering to EU Good Manufacturing Practice (GMP) standards.

Adrex Pharmaceuticals, based in Germany, holds licenses for the import, manufacture, and distribution of cannabis products. Bioxyne views this agreement as a pivotal step in its strategy for international growth, with initial shipments of 580 kilograms slated for delivery in September 2025, followed by another shipment in November. The company anticipates generating at least A$5.6 million in revenue from this deal in the 2026 financial year.

BLS has registered fourteen Australian-manufactured cannabis strains with Germany’s Federal Institute for Drugs and Medical Devices (BfArM), allowing for their importation and sale in the German market. Bioxyne has stated that BLS and Adrex are collaborating to launch the Dr Watson brand along with other BLS products in Germany.

The German medical cannabis market is rapidly expanding due to recent regulatory changes expected to take effect in early 2025, with projections indicating it could exceed Australia’s A$1 billion medical cannabis market by 2026. Cannabis flower constitutes more than 95% of Germany’s medical cannabis sales and must comply with GMP standards. As a GMP-certified manufacturer, BLS is well-equipped to expand its operations and maintain competitive pricing as it seeks additional opportunities in Germany and across the European Union.

Bioxyne aims to leverage its entry into the German market, along with planned expansions into the UK and other European Union countries, to drive substantial growth throughout fiscal year 2026.